



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/463,024	02/15/2002	G. Ganga Raju	31174/30000	5778
4743 7590 09/07/2007 MARSHALL, GERSTEIN & BORUN LLP 233 S. WACKER DRIVE, SUITE 6300 SEARS TOWER CHICAGO, IL 60606			EXAMINER AHMED, HASAN SYED	
			ART UNIT 1615	PAPER NUMBER
			MAIL DATE 09/07/2007	DELIVERY MODE PAPER

**Please find below and/or attached an Office communication concerning this application or proceeding.**

The time period for reply, if any, is set in the attached communication.

**Office Action Summary**

Application No.

09/463,024

Applicant(s)

RAJU, G. GANGA

Examiner

Hasan S. Ahmed

Art Unit

1615

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

**Period for Reply**

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

**Status**

- 1) ☒ Responsive to communication(s) filed on 14 February 2007.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

**Disposition of Claims**

- 4) ☒ Claim(s) 25-27, 29 and 31-41 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 25-27, 29, and 31-41 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

**Application Papers**

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

**Priority under 35 U.S.C. § 119**

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some \* c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
  2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- \* See the attached detailed Office action for a list of the certified copies not received.

**Attachment(s)**

- |  |   |
|--|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892)   | 4) <input type="checkbox"/> Interview Summary (PTO-413)<br>Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)                       | 5) <input type="checkbox"/> Notice of Informal Patent Application                       |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08)<br>Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____  |

### DETAILED ACTION

- Receipt is acknowledged of applicant's amendments to the claims and remarks, which were filed on 14 February 2007.
- Applicant's arguments have been considered but are moot in view of the new grounds of rejection.

\* \* \* \* \*

### ***Claim Rejections - 35 USC § 112***

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 25-27, 29, and 31-41 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claims contain subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventors, at the time the application was filed, had possession of the claimed invention.

The instant claim set recites the limitation "...a double or triple salt of hydroxycitric acid...". After carefully examining the instant disclosure, the examiner respectfully submits that support for this amendment is lacking and the addition of said limitation is new matter. Specifically, the limitation "a double or triple salt" is not set forth in the instant specification.

\* \* \* \* \*

***Claim Rejections - 35 USC § 103***

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Claims 25-27, 29, and 31-41 are rejected under 35 U.S.C. 103(a) as being unpatentable over US 5,612,039 ("Policappelli") in view of US 3,764,692 ("Lowenstein").

Policappelli teaches a dietary supplementation composition comprising the calcium salt of Garcinia Cambogia-hydroxycitric acid extract (column 3, lines 5-14 and column 5, line 60 - column 6, line 29).

According to Policappelli, the Garcinia extract can be used to reduce appetite and assist in dietary control (column 3, lines 12-14 and column 5, lines 66-67). In terms of the dosage amount, about 750 mg may be administered to an individual prior to a meal (Claims 3-4). Since the compositions can be administered to an individual prior to breakfast, lunch, and dinner, it is the examiner's position that the compositions can be administered to an individual up to three times per day (Claims 3-5).

Although Policappelli teaches a hydroxycitric acid-based composition comprising calcium, it does not teach adding potassium or sodium to the weight loss composition. However, Lowenstein teaches a salt form of hydroxycitric acid using potassium or sodium (col. 2, line 4).

Neither Policappelli nor Lowenstein explicitly teach a double or triple salt of hydroxycitric acid, however, by virtue of the chemical structure of hydroxycitric acid, i.e.

Art Unit: 1615

three carboxylic acid domains, formation of a double or triple salt is inherent. Salts (i.e. neutralized hydroxycitric acid) are formed, using for instance, sodium, calcium, or potassium hydroxide. It should be noted that the terms "double salt" and "triple salt" are recited solely in the amended claims, not in the original specification.

While neither Policappelli, nor Lowenstein explicitly teach the percentages of instant claims 25-27, it is the position of the Examiner that it would have been obvious to one of ordinary skill in the art at the time the invention was made to determine suitable percentages through routine or manipulative experimentation to obtain the best possible results, as these are variable parameters attainable within the art.

Moreover, generally, differences in concentration will not support the patentability of subject matter encompassed by the prior art unless there is evidence indicating such concentration is critical. "[W]here the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine experimentation." *In re Aller*, 220 F.2d 454, 456; 105 USPQ 233, 235 (CCPA 1955). Applicants have not demonstrated any unexpected or unusual results, which accrue from the instant percentage ranges.

Furthermore, the references are silent with respect to the properties of instant claims 35-37. Applicant's composition is the same as the prior art. It contains the same components in the same configuration. Properties are the same when the structure and composition are the same. Thus, burden shifts to applicant to show unexpected results, by declaration or otherwise. *In re Fitzgerald*, 205 USPQ 594. In the alternative, the

Art Unit: 1615

claimed properties would have been present once the composition was employed in its intended use. *In re Best*, 195 USPQ 433.

It would have been obvious to a person of ordinary skill in the art at the time the invention was made to disclose a double or triple salt of hydroxycitric acid comprising calcium and potassium or sodium, as taught by Policappelli in view of Lowenstein. One of ordinary skill in the art at the time the invention was made would have been motivated to make such a composition because it is useful reducing appetite and controlling diet, as explained by Policappelli.

\* \* \* \* \*

### ***Double Patenting***

#### **1. Statutory Type Double Patenting**

A rejection based on double patenting of the "same invention" type finds its support in the language of 35 U.S.C. 101 which states that "whoever invents or discovers any new and useful process ... may obtain a patent therefor ..." (Emphasis added). Thus, the term "same invention," in this context, means an invention drawn to identical subject matter. See *Miller v. Eagle Mfg. Co.*, 151 U.S. 186 (1894); *In re Ockert*, 245 F.2d 467, 114 USPQ 330 (CCPA 1957); and *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970).

A statutory type (35 U.S.C. 101) double patenting rejection can be overcome by canceling or amending the conflicting claims so they are no longer coextensive in scope. The filing of a terminal disclaimer cannot overcome a double patenting rejection based upon 35 U.S.C. 101.

Claims 25, 26, and 29 are provisionally rejected under 35 U.S.C. 101 as claiming the same invention as that of claims 3-5, 7-9, 12 of copending Application No.11/209429 ('429). This is a provisional double patenting rejection since the conflicting claims have not in fact been patented. '429 claims compositions comprising (1) hydroxycitric acid in the amount of approximately 55-65%, calcium in an amount of

Art Unit: 1615

either 14 - 26% by weight or 9 - 13% by weight (depending on how the percentage by weight is calculated), potassium in an amount of either 24 - 40% by weight or, 9-20% by weight, or 14 - 18% by weight (depending on how the percentage by weight is calculated), or sodium in an amount of either 14 - 24% by weight or 5 - 12% by weight (depending on how the percentage by weight is calculated), and mixtures thereof. The above limitations are the same ones as set forth in the instant claims 25, 26, and 29.

\*

## 2. Obviousness-Type Double Patenting

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., *In re Berg*, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement.

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Claims 25-27, 29, and 31-41 are provisionally rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-2, 6, 10-11, 13-36 of copending Application No. 11/209429 ('429). Although the conflicting

Art Unit: 1615

claims are not identical, they are not patentably distinct from each other because '429 claims compositions comprising (1) hydroxycitric acid in the amount of approximately 40-65%, calcium in an amount of either 14 - 26% by weight or 9 - 13% by weight (depending on how the percentage by weight is calculated), potassium in an amount of either 24 - 40% by weight or, 9-20% by weight, or 14 - 18% by weight (depending on how the percentage by weight is calculated), or sodium in an amount of either 14 - 24% by weight or 5 -12% by weight (depending on how the percentage by weight is calculated), and mixtures thereof. Like the instant claim set, the composition claimed by '429 can be used as a food product and is suitable for reducing body weight.

Because '429 claims a food product comprising hydroxycitric acid, calcium, and potassium or sodium, and claims that said product can be used to reduce body weight (claim 15, 26, 28), the examiner respectfully suggests that one of ordinary skill in the art at the time the invention was made would have the requisite motivation to claim a food composition comprising hydroxycitric acid, calcium, potassium, or sodium as well as a method of using said composition to reduce body weight. The expected result of such a combination would be an effective weight reducing food composition. As such, given the claims of '429, one of ordinary skill in the art at the time the invention was made would have the motivation to claim a food composition comprising hydroxycitric acid, calcium, potassium, or sodium as well as a method of using said composition to reduce body weight.

This is a provisional obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.



★


**Correspondence**

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Hasan S. Ahmed whose telephone number is 571-272-4792. The examiner can normally be reached on 9am - 5:30pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Michael P. Woodward can be reached on 571-272-8373. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

\*\*\*

  
HOMERA M. SHEIKH  
PRIMARY EXAMINER